M/s. Moraf Pharmaceuticals Ltd Pharmaceutical Import Profile — Tanzania (DGFT 2022–2026)

Name: M/s. Moraf Pharmaceuticals Ltd Pharmaceutical Import Records from India — 2 Products, $450.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Moraf Pharmaceuticals Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $450.0K Trade | TransData Nexus

M/s. Moraf Pharmaceuticals Ltd

Pharmaceutical Importer · Tanzania · Antifungals Focus · $450.0K Total Trade · DGFT Verified

M/s. Moraf Pharmaceuticals Ltd is a pharmaceutical importer based in Tanzania with a total trade value of $450.0K across 2 products in 2 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Moraf Pharmaceuticals Ltd sources from 1 verified Indian supplier, with Fourrts (india) Laboratories Private Limited accounting for 100.0% of imports.

M/s. Moraf Pharmaceuticals Ltd — Import Portfolio & Supplier Network

M/s. Moraf Pharmaceuticals Ltd import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Moraf Pharmaceuticals Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fourrts (india) Laboratories Private Limited	$1.3M	40	100.0%

M/s. Moraf Pharmaceuticals Ltd sources from 1 verified Indian supplier across 19 distinct formulations. The sourcing is highly concentrated — Fourrts (india) Laboratories Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Paracetamol tablets BP 500MG (parafil)	$200.0K	4
Ibuprofen tablets BP 200MG (ibufil 200)	$137.4K	4
Fungifen v cream (58075 x 30g)	$117.4K	3
Salbutamol tablets BP 4MG (salfil 4)	$114.3K	3
Fluconazole capsules USP 150MG	$107.0K	3
Quadrajel (chlorhexidine gluconate IP	$103.0K	3
Maxxsat 100 (sildenafil tablets 100MG)	$102.1K	3
Maxxsat 50 (sildenafil tablets 50MG)	$101.9K	3
Edsave 20 (tadalafil tablets USP 20MG)	$101.1K	3
Fluconazole capsules 150MG (fungistop	$100.0K	2
Metronidazole suspension (fogyl	$19.9K	1
Salbutamol tablets BP 4MG (salfil 4)	$18.2K	1
Paediatric paracetamol oral solution	$14.5K	1
Sucralfate USP 1g (sucrafil suspension)	$9.9K	1
Glibenclamide BP 5MG + metformin	$9.8K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluconazole	Antifungals	$250.0K	5	0.3%	9
2	Salbutamol	Respiratory	$200.0K	4	0.1%	8

M/s. Moraf Pharmaceuticals Ltd imports 2 pharmaceutical products across 2 categories into Tanzania totaling $450.0K.

M/s. Moraf Pharmaceuticals Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Moraf Pharmaceuticals Ltd is a privately held pharmaceutical company headquartered in Dar es Salaam, Tanzania. Established in 2000, the company has grown to employ between 201 and 500 individuals. It operates as an importer and distributor of pharmaceutical and surgical products, aiming to ensure the accessibility of safe, effective, and affordable healthcare products across Tanzania. Their primary imports originate from countries such as India, China, and Kenya.

The company's mission focuses on reaching even the remotest areas of Tanzania, supplying hospitals, pharmacies, and medical institutions with essential healthcare products. This commitment underscores their role in enhancing the nation's healthcare infrastructure by providing a diverse range of pharmaceutical and surgical items.

2Distribution Network

Moraf Pharmaceuticals Ltd's distribution network is centralized in Dar es Salaam, with their main office located on Kipande Street in the Kariakoo area. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Dar es Salaam suggests a focus on efficient distribution within Tanzania. The choice of Dar es Salaam, a major port city, likely facilitates the importation and distribution of pharmaceutical products throughout the country.

3Industry Role

In Tanzania's pharmaceutical supply chain, Moraf Pharmaceuticals Ltd functions primarily as a wholesaler and distributor. By importing pharmaceutical and surgical products and supplying them to hospitals, pharmacies, and medical institutions, the company plays a crucial role in ensuring the availability of essential healthcare products across the nation. Their operations are integral to the healthcare sector, supporting the delivery of medical services by providing necessary supplies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Moraf Pharmaceuticals Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Moraf Pharmaceuticals Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value of $450,000 USD from India across nine shipments, all sourced from a single supplier: FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED. This single-source dependency indicates a strategic choice to maintain a consistent supply chain and potentially leverage favorable terms with a trusted supplier. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier terms. The absence of alternative suppliers in the data suggests a need for diversification to mitigate potential risks.

2Supply Chain Resilience

The resilience of Moraf Pharmaceuticals Ltd's supply chain appears limited due to its reliance on a single supplier for all imports. This lack of diversification could expose the company to significant risks if the supplier faces operational challenges or if there are disruptions in the shipping routes from India. Additionally, the data does not indicate the presence of backup suppliers or a diverse range of formulations, which are essential for maintaining a robust supply chain. Ensuring regulatory compliance of the key supplier is crucial, as any lapses could directly impact Moraf Pharmaceuticals Ltd's operations.

Strategic Implications

Importing Pharmaceuticals into Tanzania — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Tanzania

1Regulatory Authority & Framework

In Tanzania, the Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of medicines and medical devices. Established under the Tanzania Medicines and Medical Devices Act, Cap. 219, TMDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Tanzanian market. (tmda.go.tz)

The regulatory framework governing pharmaceutical imports includes the Pharmaceutical and Poisons Act, which stipulates that no person shall import any pharmaceutical product unless it is registered and the importer holds the appropriate license issued by the Board. This legislation ensures that all imported pharmaceutical products meet the required standards before entering the Tanzanian market.

2Import Licensing & GMP

Importers of pharmaceutical products in Tanzania must obtain an import license from TMDA. The application process involves submitting necessary documents and paying the prescribed fees. Importers are also required to register their premises with TMDA before applying for permits. Compliance with the conditions prescribed under the Guidelines for Importation and Exportation of Pharmaceutical Products is mandatory. (tmda.go.tz)

Regarding Good Manufacturing Practice (GMP), imported pharmaceutical products must come from facilities that adhere to recognized GMP standards. TMDA requires that pharmaceutical products imported into Tanzania be from manufacturers with GMP certification to ensure product quality and safety. (tmda.go.tz)

M/s. Moraf Pharmaceuticals Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Moraf Pharmaceuticals Ltd's focus on importing antifungal and respiratory medications aligns with the prevalent health concerns in Tanzania. The significant import value of fluconazole and salbutamol indicates a strategic approach to addressing common medical conditions such as fungal infections and respiratory disorders. This product strategy is driven by market demand and the company's commitment to providing essential healthcare solutions to the Tanzanian population.

2Sourcing Profile

Moraf Pharmaceuticals Ltd's sourcing strategy is heavily reliant on importing finished pharmaceutical formulations from India, particularly from FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED. This approach suggests a preference for ready-to-use products that meet the company's quality standards. The focus on finished formulations indicates a streamlined procurement process, allowing the company to efficiently supply the Tanzanian market with essential medications.

3Market Positioning

Based on its product mix, Moraf Pharmaceuticals Ltd serves a broad segment of the Tanzanian market, including retail pharmacies, hospitals, and government tenders. By supplying essential medications such as antifungals and respiratory drugs, the company plays a pivotal role in the healthcare supply chain, ensuring that various healthcare providers have access to necessary pharmaceutical products.

Seller's Guide — How to Become a Supplier to M/s. Moraf Pharmaceuticals Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Moraf Pharmaceuticals Ltd. The company's current sourcing pattern, characterized by a high concentration on a single supplier, presents an opportunity for diversification. Indian exporters can offer competitive pricing, diverse product formulations, and reliable delivery schedules to meet the company's needs. Identifying gaps in the current sourcing strategy, such as the need for additional suppliers or alternative products, can further enhance the partnership potential.

2Requirements & Qualifications

Indian exporters seeking to supply Moraf Pharmaceuticals Ltd and the Tanzanian market must ensure that their products are registered with TMDA. Compliance with TMDA's import licensing requirements, including the registration of premises and adherence to GMP standards, is mandatory. Additionally, products must meet labeling requirements, including information in the English language and specific product details. Ensuring that products have an adequate remaining shelf-life upon importation is also crucial. (tmda.go.tz)

3How to Approach

Frequently Asked Questions — M/s. Moraf Pharmaceuticals Ltd

What products does M/s. Moraf Pharmaceuticals Ltd import from India?

M/s. Moraf Pharmaceuticals Ltd imports 2 pharmaceutical products across 2 categories. Top imports: Fluconazole ($250.0K), Salbutamol ($200.0K).

Who supplies pharmaceuticals to M/s. Moraf Pharmaceuticals Ltd from India?

M/s. Moraf Pharmaceuticals Ltd sources from 1 verified Indian suppliers. The primary supplier is Fourrts (india) Laboratories Private Limited (100.0% of imports, $1.3M).

What is M/s. Moraf Pharmaceuticals Ltd's total pharmaceutical import value?

M/s. Moraf Pharmaceuticals Ltd's total pharmaceutical import value from India is $450.0K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Moraf Pharmaceuticals Ltd focus on?

M/s. Moraf Pharmaceuticals Ltd imports across 2 categories. The largest: Antifungals (55.6%), Respiratory (44.4%).

Get Full M/s. Moraf Pharmaceuticals Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.